ELI LILLY & CoLLY
ELI LILLY & Co Financial Overview 2021–2025
Updated Jul 10, 2026Eli Lilly’s incretin franchise has fundamentally rewired its earnings profile, with Mounjaro and Zepbound combining to generate 56% of total revenues in FY2025. This concentrated demand validates the central investment thesis: the company has successfully transitioned from a legacy pharmaceutical manufacturer into a hyper-growth cardiometabolic powerhouse, unlocking unprecedented profitability by dominating the global obesity and diabetes markets.
The sheer velocity of this transformation is evident across the five-year horizon. Total revenue scaled from $28.3 billion in FY2021 to $65.18 billion in FY2025, fueled by a 45% year-over-year revenue jump in the final twelve months. This top-line explosion vastly outpaced rising clinical costs, allowing net income to surge 95% to $20.64 billion in FY2025 even as research and development expenses expanded to $13.34 billion. The company aggressively leveraged this cash generation, authorizing a $15.0 billion share repurchase program late in FY2024 and deploying billions into fixed-rate debt to rapidly expand its international manufacturing capacity.
The market has heavily priced in this structural growth. At the close of FY2025, the stock traded at 46.8x earnings and closed at $1074.68 per share. Investors are directly rewarding Eli Lilly's ability to commercialize pipeline breakthroughs into immediate cash flow, prioritizing the massive commercial upside of its weight-loss assets over impending government-set pricing controls and persistent supply chain bottlenecks.
Recent Developments (Q4 2025 and Q1 2026)
In Q1 2026, revenue posted a 56% increase year-over-year to $19.8 billion, driving a 168% increase in net income to $7.4 billion. Gross margins expanded while acquired in-process R&D charges plummeted 63% to $584 million. The company subsequently acquired Ventyx Biosciences for $1.1 billion in March 2026 and raised $8.94 billion via new debt offerings. Management also executed $2.3 billion in quarterly share repurchases.
The bull case centers on a 170% jump in diluted EPS to $8.26, demonstrating the ability to scale volume while expanding operational profitability. Conversely, the bear case highlights rising overhead, including a 28% increase in R&D expenses to $3.5 billion, alongside risks of mandatory debt redemptions if the proposed Centessa acquisition fails. At 40.7x earnings as of April 30, 2026, the valuation remains steep but reflects persistent hyper-growth.
What to watch: integration of the Ventyx Biosciences portfolio; progress on the pending Centessa buyout.
Rev
$65.18B
FY2025
NI
$20.64B
FY2025
EPS
$23.00
FY2025
OCF
$16.81B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
ELI LILLY & Co 8-K Report, Corporate Update (May 20, 2026)
Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $8.94 billion in net proceeds. This offering comprised multiple tranches of both floating rate and fixed rate notes with varying maturity dates and interest rates, ranging from 2028 to 2066. The issuance of these notes was registered under a Form S-3 shelf registration statement, indicating Lilly's proactive capital management strategy. The substantial capital infusion is poised to support the company's ongoing operations, strategic initiatives, and potential future investments. A notable aspect of this offering is the conditional mandatory redemption for certain series of notes tied to the consummation of the 'Centessa Acquisition'. Should this acquisition not proceed under specified conditions, specific series of notes will be subject to redemption at 101% of their principal amount, plus accrued interest, highlighting a potential contingent liability for the company dependent on M&A outcomes.
ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 7, 2026)
Eli Lilly and Company (LLY) held its 2026 Annual Meeting of Shareholders on May 4, 2026, with a strong turnout of approximately 90% of outstanding shares participating in the vote. Key outcomes include the re-election of four directors, Carolyn Bertozzi, William Kaelin, Jr., Jon Moeller, and David Ricks, to three-year terms. Additionally, shareholders provided advisory approval for the compensation of named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026, both with significant support. However, two significant proposals to amend the Company's Articles of Incorporation, one to eliminate the classified board structure and another to remove supermajority voting provisions, failed to gain the required 80% approval from outstanding shares. Furthermore, shareholder proposals requesting an independent board chair and an annual lobbying report were also not approved. These voting results indicate continued shareholder confidence in the current board and executive compensation practices, while also highlighting resistance to certain governance structure changes at this time.
ELI LILLY & Co 8-K Report, Financial Results (Apr 30, 2026)
Eli Lilly and Company (LLY) has filed a Current Report on Form 8-K dated April 30, 2026, to announce its financial results for the quarter ended March 31, 2026. The report primarily consists of a press release (Exhibit 99.1) detailing these financial outcomes. While the filing itself does not contain the specific financial figures or operational details, it serves as a formal notification to investors that this information has been disseminated. Investors seeking detailed insights into Lilly's performance for the first quarter of 2026 should refer to the attached press release, which is incorporated by reference into this filing.
ELI LILLY & Co 8-K Report, Financial Results (Feb 4, 2026)
Eli Lilly and Company (LLY) filed a 8-K Current Report on February 4, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily incorporates by reference a press release (Exhibit 99.1) containing these detailed financial outcomes. While the filing itself is brief, the associated press release is the critical document for investors seeking to understand the company's recent performance, including key revenue drivers, profitability, and any forward-looking statements or guidance provided by management.
ELI LILLY & Co 8-K Report, Executive Changes (Nov 21, 2025)
Eli Lilly & Company (LLY) announced a significant addition to its Board of Directors, electing Dr. Carolyn R. Bertozzi, a distinguished professor from Stanford University and Howard Hughes Medical Institute investigator, effective December 8, 2025. Dr. Bertozzi brings a wealth of expertise in Chemistry, Chemical & Systems Biology, and Radiology, positions that will be highly relevant to Lilly's ongoing innovation and development in the pharmaceutical sector. Her appointment is intended to bolster the Board's strategic direction, particularly through her service on the Science and Technology Committee and the Ethics and Compliance Committee. Dr. Bertozzi's independence has been confirmed, and she will participate in the company's standard director compensation. This move signals Lilly's commitment to leveraging cutting-edge scientific knowledge at the highest governance level.
View all 8-K filings →